Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.37 |
| ▸ | USP2 | O75604 | 7/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18497005 | 0.91 | ALDH1A1 (0.36) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL5566107 | 0.82 | CYP2D6 (0.36) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL17009549 | 0.78 | CYP2D6 (0.36) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL28501410 | 0.78 | PTGER2 (0.40) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL23536294 | 0.77 | CYP2D6 (0.34) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL1119769 | 0.75 | USP2 (0.36) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL2209078 | 0.74 | ALDH1A1 (0.37) | ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL5380076 | 0.73 | HSD11B1 (0.48) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL15716997 | 0.73 | USP2 (0.36) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL28170910 | 0.72 | CYP3A4 (0.34) | CYP3A4USP2CYP2C19HSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8603975-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-2150269-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, ZC3HAV1 | CYP3A4 4773/4885USP2 4089/4885CYP2C19 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.